The Cancer Letter

The leading source for information on the issues that shape oncology since 1973

Clinical

Imbruvica Shows Response in 2/3 of Steroid Dependent, Refractory cGVHD Patients in Phase II Study

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
BYLINE
IN THIS ISSUE
DOWNLOAD PDFTABLE OF CONTENTS

In a phase II study, ibrutinib (Imbruvica) demonstrated clinically meaningful and durable responses and reduced symptom severity, with an overall response rate of 67% in patients with cGVHD.

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe

YOU MAY BE INTERESTED IN

In Brief

John Leonard named director of Center for Blood Cancers, chief of Division of Hematology and Medical Oncology at NYU Langone

John P. Leonard, an expert in lymphoma and other blood cancers, was named director of the Center for Blood Cancers and chief of the Division of Hematology and Medical Oncology in NYU Grossman School of Medicine’s Department of Medicine. The Division of Hematology and Medical Oncology is a major clinical arm of the Perlmutter Cancer Center.

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login

Site license subscribers:
Log in with your IP | Register a sponsored account